Citigroup has upgraded its rating for Hims & Hers Health Inc. (HIMS.US) from "Sell" to "Neutral," while significantly raising its price target from $13.25 to $24. Based on the closing price on March 9, this new target implies approximately 8% upside potential. This adjustment is primarily based on a key recent agreement between the company and Novo-Nordisk A/S (NVO.US). By acting as a distributor for Novo-Nordisk's GLP-1 medications for weight loss and type 2 diabetes treatment, Hims & Hers Health has substantially mitigated several business risks previously concerning the market. These include issues such as a narrow product pipeline, competitive market pressures, and regulatory uncertainties. In its latest research report, Citi gave this collaboration a highly positive assessment, viewing it as a significant turning point in the development of Hims & Hers. Citi analysts noted that by introducing officially licensed medications, Hims & Hers has successfully moved beyond the compliance concerns and legal risks that had long troubled its business model. This transition from selling "compounded generic versions" to becoming an "official partner" not only greatly enhances the sustainability of its business but also allows it to penetrate more deeply into the lucrative weight-loss healthcare market. This positive news triggered a sharp rebound in the secondary market. Following the announcement, the stock price of Hims & Hers surged more than 35% during the trading session and closed up 40.79% on Monday at $22.16. Market investors widely believe that Novo-Nordisk's choice to leverage Hims' strong telemedicine channels and brand influence will accelerate the adoption rate of its weight-loss drugs among consumers. Meanwhile, Hims & Hers has solidified its leadership position in the digital healthcare sector through this deal. Although the specific pricing for Wegovy and Ozempic sold through Hims & Hers' channels has not been publicly disclosed, analyst Daniel Grosslight predicts that the average monthly price for these drugs will be approximately $100 higher than the out-of-pocket cash price on Novo-Nordisk's official NovoCare platform. This premium is primarily attributed to the value-added services bundled by Hims & Hers—customers receive support from a professional medical team, personalized nutrition plans, and exercise guidance alongside the medication, creating a combined "drugs plus services" package. Concurrently, Grosslight highlighted a potential risk clause in the cooperation agreement: according to the terms, Hims & Hers must cease large-scale in-house compounding of semaglutide, the core active ingredient in Wegovy and Ozempic. This restriction could significantly impact its revenue structure, potentially leading to a substantial decline in the company's revenue and adjusted EBITDA.
Comments